- Home
- EXAS vs MASI Comparison
EXAS vs MASI Comparison
Compare EXAS & MASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- MASI
- Stock Information
- Founded
- EXAS 1995
- MASI 1989
- Country
- EXAS United States
- MASI United States
- Employees
- EXAS N/A
- MASI N/A
- Industry
- EXAS Medical Specialities
- MASI Medical/Dental Instruments
- Sector
- EXAS Health Care
- MASI Health Care
- Exchange
- EXAS Nasdaq
- MASI Nasdaq
- Market Cap
- EXAS 10.1B
- MASI 8.9B
- IPO Year
- EXAS N/A
- MASI 2007
- Fundamental
- Price
- EXAS $48.49
- MASI $164.62
- Analyst Decision
- EXAS Strong Buy
- MASI Buy
- Analyst Count
- EXAS 20
- MASI 6
- Target Price
- EXAS $70.26
- MASI $187.00
- AVG Volume (30 Days)
- EXAS 2.6M
- MASI 552.6K
- Earning Date
- EXAS 08-06-2025
- MASI 08-05-2025
- Dividend Yield
- EXAS N/A
- MASI N/A
- EPS Growth
- EXAS N/A
- MASI N/A
- EPS
- EXAS N/A
- MASI N/A
- Revenue
- EXAS $2,828,128,000.00
- MASI $2,126,800,000.00
- Revenue This Year
- EXAS $14.61
- MASI N/A
- Revenue Next Year
- EXAS $12.65
- MASI $7.74
- P/E Ratio
- EXAS N/A
- MASI N/A
- Revenue Growth
- EXAS 11.57
- MASI 16.68
- 52 Week Low
- EXAS $39.97
- MASI $101.61
- 52 Week High
- EXAS $72.83
- MASI $194.88
- Technical
- Relative Strength Index (RSI)
- EXAS 38.76
- MASI 53.25
- Support Level
- EXAS $48.15
- MASI $153.36
- Resistance Level
- EXAS $53.95
- MASI $166.96
- Average True Range (ATR)
- EXAS 2.10
- MASI 4.06
- MACD
- EXAS -0.51
- MASI 0.06
- Stochastic Oscillator
- EXAS 4.39
- MASI 72.88
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About MASI Masimo Corporation
Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.